Aton Ra Partners Legend Biotech Corp Transaction History

Aton Ra Partners

$50.1 Million
Q4 2023

A detailed history of Aton Ra Partners transactions in Legend Biotech Corp stock. As of the latest transaction made, Aton Ra Partners holds 8,847 shares of LEGN stock, worth $290,181. This represents 1.06% of its overall portfolio holdings.

Number of Shares

8,847

Previous 9,912 10.74%

Holding current value

$290,181

Previous $665,000 20.0%

% of portfolio

1.06%

Previous 1.4%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$57.25 - $69.74 $60,971 - $74,273	-1,065 Reduced 10.74%	8,847 $532,000
Q3 2023 Oct 25, 2023	SELL	$63.16 - $76.5 $446,541 - $540,855	-7,070 Reduced 41.63%	9,912 $665,000
Q2 2023 Jul 18, 2023	SELL	$46.28 - $75.01 $42,947 - $69,609	-928 Reduced 5.18%	16,982 $1.17 Million
Q1 2023 May 05, 2023	SELL	$43.42 - $57.37 $91,138 - $120,419	-2,099 Reduced 10.49%	17,910 $863,000
Q4 2022 Feb 02, 2023	SELL	$38.8 - $55.46 $315,870 - $451,499	-8,141 Reduced 28.92%	20,009 $998,000
Q3 2022 Nov 14, 2022	SELL	$38.15 - $57.1 $839 - $1,256	-22 Reduced 0.08%	28,150 $1.15 Million
Q2 2022 Aug 15, 2022	SELL	$33.54 - $55.0 $763,236 - $1.25 Million	-22,756 Reduced 44.68%	28,172 $1.55 Million
Q1 2022 May 16, 2022	SELL	$31.02 - $48.18 $369,789 - $574,353	-11,921 Reduced 18.97%	50,928 $1.85 Million
Q4 2021 Feb 14, 2022	BUY	$41.14 - $56.98 $1.21 Million - $1.67 Million	29,356 Added 87.65%	62,849 $2.93 Million
Q3 2021 Nov 15, 2021	BUY	$35.31 - $50.56 $1.18 Million - $1.69 Million	33,493 New	33,493 $1.69 Million

Others Institutions Holding LEGN

# of Institutions

225

Shares Held

74.3M

Call Options Held

279K

Put Options Held

350K

View Full List

About Legend Biotech Corp

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $5.49B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

More about LEGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aton Ra Partners, based on Form 13F filings with the SEC.

News

Stay updated on Aton Ra Partners with notifications on news.

Account